Zydus Lifesciences Limited fell 1.5% after the US Food and Drug Administration inspected its Moraiya, Ahmedabad manufacturing facility from October 5 to 13, concluding with five observations.

Zydus Lifesciences said the US Food and Drug Administration has accepted for review its Biologics License Application for FYB206, a biosimilar of MSD's Keytruda, with a decision expected in the third quarter of 2027 and exclusive US and Canada commercialisation rights held by Zydus.

Zydus Lifesciences Limited rose 0.83% to Rs 1,121.20 on the NSE after Nomura retained its Buy rating, citing Indian Pharmaceutical Market growth of 13.5% year-on-year in September. Nomura said Zydus led growth among the top 20 companies with sales up 23.5% year-on-year in September and 20.6% year-on-year for the quarter ended 2QFY27.

Zydus Lifesciences shares fell 2.49% to Rs 1,124.30 after the Supreme Court directed the Centre to constitute a committee to examine measures to prevent pharma companies from offering expensive gifts and incentives to doctors.

Zydus Lifesciences Limited declined 1.5% after Bernstein retained its Outperform rating on the company with a target price of Rs 1,457 per share.